Nature Medicine

Gut and urogenital microbiomes influence menopausal hormone therapy outcomes
https://www.nature.com/articles/s41591-026-04789-6

Nature Medicine, Published online: 13 November 2026; doi:10.1038/s41591-026-04789-6 (https://www.nature.com/articles/s41591-026-04789-6)A 6-month study shows that menopausal hormone therapy induces multi-site microbiome remodeling, including rejuvenation of the vaginal microbial community toward a reproductive-age-like state. In turn, baseline gut and vaginal community types affect the clinical response to therapy. Integrating clinical and gut microbiome features predicts rapid symptom remission, providing a blueprint for precision menopausal care.

Effect of two common GVHD prophylaxis regimens on the gut microbiome in a randomized phase 3 trial
https://www.nature.com/articles/s41591-026-04712-z

Nature Medicine, Published online: 12 November 2026; doi:10.1038/s41591-026-04712-z (https://www.nature.com/articles/s41591-026-04712-z)In a prespecified companion study (BMT CTN 1801) of the randomized phase 3 BMT CTN 1703 trial comparing two common GVHD prophylaxis regimens, microbiome diversity at engraftment did not associate with non-relapse mortality, but secondary analyses found baseline microbiome diversity was associated with clinical outcomes.

Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer
https://www.nature.com/articles/s41591-026-04716-9

Nature Medicine, Published online: 11 November 2026; doi:10.1038/s41591-026-04716-9 (https://www.nature.com/articles/s41591-026-04716-9)This work developed and validated a computational pathology biomarker—the TROP2 normalized membrane ratio—that quantifies subcellular TROP2 localization and predicts improved progression-free and overall survival with datopotamab deruxtecan in patients with nonsquamous non-small-cell lung cancer lacking actionable genomic alterations.